NCT06567457View on ClinicalTrials.gov

Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 31, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

intramuscular injection

BIOLOGICAL

SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

intramuscular injection

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY